Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bates

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Current Pharmaceutical Design|July 29, 2004
A review of depsipeptide and other histone deacetylase inhibitors in clinical trialsRichard Piekarz, Susan Bates
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Arsenic trioxide (As(2)O(3)): still a mysteryTito Fojo, Susan Bates
Oncogene|October 25, 2003
Strategies for reversing drug resistanceTito Fojo, Susan Bates
Cancer Discovery|January 16, 2013
Mechanisms of resistance to PARP inhibitors--three and countingTito Fojo, Susan Bates
JAMA Oncology|May 22, 2025
Skimming the Median and the Problem of Exaggerated Survival GainsTito Fojo, Susan Bates
The Oncologist|October 7, 2017
Clinical Trials in Pancreatic Cancer: A Long SlogThomas Enzler, Susan Bates
Nature Reviews. Clinical Oncology|July 15, 2015
Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubulesAgnes Basseville, Susan Bates, Tito Fojo
Nature Reviews. Cancer|April 2, 2005
Tumour stem cells and drug resistanceMichael Dean, Tito Fojo, Susan Bates
The Biochemical Journal|May 14, 2004
Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing bindingOmar Alqawi, Susan Bates, Elias Georges
American Journal of Clinical Dermatology|September 3, 2018
Current Status of HDAC Inhibitors in Cutaneous T-cell LymphomaAdriana T Lopez, Susan Bates, Larisa Geskin
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Design|July 29, 2004
A review of depsipeptide and other histone deacetylase inhibitors in clinical trialsRichard Piekarz, Susan Bates
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Arsenic trioxide (As(2)O(3)): still a mysteryTito Fojo, Susan Bates
Oncogene|October 25, 2003
Strategies for reversing drug resistanceTito Fojo, Susan Bates
Cancer Discovery|January 16, 2013
Mechanisms of resistance to PARP inhibitors--three and countingTito Fojo, Susan Bates
JAMA Oncology|May 22, 2025
Skimming the Median and the Problem of Exaggerated Survival GainsTito Fojo, Susan Bates
The Oncologist|October 7, 2017
Clinical Trials in Pancreatic Cancer: A Long SlogThomas Enzler, Susan Bates
Nature Reviews. Clinical Oncology|July 15, 2015
Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubulesAgnes Basseville, Susan Bates, Tito Fojo
Nature Reviews. Cancer|April 2, 2005
Tumour stem cells and drug resistanceMichael Dean, Tito Fojo, Susan Bates
The Biochemical Journal|May 14, 2004
Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing bindingOmar Alqawi, Susan Bates, Elias Georges
American Journal of Clinical Dermatology|September 3, 2018
Current Status of HDAC Inhibitors in Cutaneous T-cell LymphomaAdriana T Lopez, Susan Bates, Larisa Geskin
Pageof 4